This episode of DeviceTalks AI explores the potential for data-driven innovation in healthcare, through conversations with leaders at Microsoft and 1910 Genetics.

In the first segment, Elena Bonfiglioli, Global Business Leader for Healthcare, Pharma and Life Sciences at Microsoft, discusses the significance of computation, an essential element of AI investments, in enhancing R&D productivity in healthcare. She emphasizes the need for new approaches to drug development, including shorter clinical trial timelines and the shift toward more efficient R&D. Bonfiglioli also highlights the importance of multimodal data in research and development. In addition, speaks to the integral role of computational methods in drug development, emphasizing how they augment our disease understanding and clinical trial design.

In the second segment, Jen Nwankwo, PhD, Founder & CEO of 1910 Genetics - a Y Combinator and Sam Altman-backed startup, shares the innovation strategies around drug discovery. She details their problem-first approach, leading to an integrated, modality-agnostic drug discovery tech stack. Dr. Nwankwo highlights the use of Azure Quantum Elements in accelerating molecular simulations, positioning 1910 Genetics uniquely in designing both small and large molecules. Their global approach to accessible drug discovery through strategic partnerships is emphasized.

Join us for the next episode of DeviceTalks AI, featuring an exclusive interview with Ben Newton, Chief Digital Officer and GM of Oncology at GE Healthcare.

Thank you to our contributors, some of whom include Catalyze Healthcare and SmartTRAK Business Intelligence, for providing invaluable support.

Tune in and subscribe to DeviceTalks AI on all major podcast channels and follow youtube.com/@DeviceTalks to ensure you never miss an episode.

WATCH, LISTEN, and READ. Thank you for supporting DeviceTalks AI!

Read Now: www.drugdiscoverytrends.com/microsoft-1910-genetics-data-hidden-gems